JP5177785B2 - 周術期患者用薬剤 - Google Patents
周術期患者用薬剤 Download PDFInfo
- Publication number
- JP5177785B2 JP5177785B2 JP2005319615A JP2005319615A JP5177785B2 JP 5177785 B2 JP5177785 B2 JP 5177785B2 JP 2005319615 A JP2005319615 A JP 2005319615A JP 2005319615 A JP2005319615 A JP 2005319615A JP 5177785 B2 JP5177785 B2 JP 5177785B2
- Authority
- JP
- Japan
- Prior art keywords
- body temperature
- administration
- inhibitor
- perioperative
- isoleucine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title description 30
- 229940079593 drug Drugs 0.000 title description 26
- 230000036760 body temperature Effects 0.000 claims description 59
- 239000003112 inhibitor Substances 0.000 claims description 36
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 claims description 25
- 108010044940 alanylglutamine Proteins 0.000 claims description 19
- 239000004480 active ingredient Substances 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 7
- 206010002091 Anaesthesia Diseases 0.000 claims description 5
- 229960002648 alanylglutamine Drugs 0.000 claims description 5
- 230000037005 anaesthesia Effects 0.000 claims description 5
- 229940024606 amino acid Drugs 0.000 description 31
- 235000001014 amino acid Nutrition 0.000 description 31
- 150000001413 amino acids Chemical class 0.000 description 31
- 238000001802 infusion Methods 0.000 description 31
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 30
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 25
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 25
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 25
- 229960000310 isoleucine Drugs 0.000 description 25
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 25
- 229960003136 leucine Drugs 0.000 description 25
- 239000000863 peptide conjugate Substances 0.000 description 20
- 238000002360 preparation method Methods 0.000 description 20
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 19
- 229960003767 alanine Drugs 0.000 description 19
- 239000000243 solution Substances 0.000 description 18
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 17
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 17
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 17
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 17
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 17
- 235000004279 alanine Nutrition 0.000 description 17
- 229960002743 glutamine Drugs 0.000 description 17
- 229960002429 proline Drugs 0.000 description 17
- 229960001153 serine Drugs 0.000 description 17
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 16
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 15
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 15
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 15
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 15
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 15
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 15
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 15
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 15
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 15
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 15
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 15
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 15
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 15
- 239000004473 Threonine Substances 0.000 description 15
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 15
- 229960001230 asparagine Drugs 0.000 description 15
- 235000009582 asparagine Nutrition 0.000 description 15
- 229960002989 glutamic acid Drugs 0.000 description 15
- 235000013922 glutamic acid Nutrition 0.000 description 15
- 239000004220 glutamic acid Substances 0.000 description 15
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 15
- 229960002885 histidine Drugs 0.000 description 15
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 15
- 229960003104 ornithine Drugs 0.000 description 15
- 229960005190 phenylalanine Drugs 0.000 description 15
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 15
- 229960003080 taurine Drugs 0.000 description 15
- 229960002898 threonine Drugs 0.000 description 15
- 229960004441 tyrosine Drugs 0.000 description 15
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 15
- 229960004295 valine Drugs 0.000 description 15
- 239000004474 valine Substances 0.000 description 15
- 235000014393 valine Nutrition 0.000 description 15
- 230000037007 arousal Effects 0.000 description 14
- 239000002504 physiological saline solution Substances 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 12
- 230000003444 anaesthetic effect Effects 0.000 description 11
- 239000003792 electrolyte Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 235000013305 food Nutrition 0.000 description 9
- 238000001356 surgical procedure Methods 0.000 description 9
- 239000004471 Glycine Substances 0.000 description 8
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 8
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 8
- 229960005261 aspartic acid Drugs 0.000 description 8
- 235000003704 aspartic acid Nutrition 0.000 description 8
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 8
- 229960002433 cysteine Drugs 0.000 description 8
- 235000018417 cysteine Nutrition 0.000 description 8
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 8
- 229960002449 glycine Drugs 0.000 description 8
- -1 inorganic acid salt Chemical class 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 8
- 229960004134 propofol Drugs 0.000 description 8
- 230000015556 catabolic process Effects 0.000 description 7
- 235000000346 sugar Nutrition 0.000 description 7
- 230000029663 wound healing Effects 0.000 description 7
- 102000008934 Muscle Proteins Human genes 0.000 description 6
- 108010074084 Muscle Proteins Proteins 0.000 description 6
- 239000004372 Polyvinyl alcohol Substances 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 239000000825 pharmaceutical preparation Substances 0.000 description 6
- 229920002451 polyvinyl alcohol Polymers 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- 238000005259 measurement Methods 0.000 description 5
- 229940127557 pharmaceutical product Drugs 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 238000010792 warming Methods 0.000 description 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- 206010062519 Poor quality sleep Diseases 0.000 description 4
- 206010063837 Reperfusion injury Diseases 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000003111 delayed effect Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000002695 general anesthesia Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 229960002897 heparin Drugs 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 210000004731 jugular vein Anatomy 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 238000001243 protein synthesis Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 4
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical class NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 102100030840 AT-rich interactive domain-containing protein 4B Human genes 0.000 description 2
- 206010008531 Chills Diseases 0.000 description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 2
- 101000792935 Homo sapiens AT-rich interactive domain-containing protein 4B Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 208000001871 Tachycardia Diseases 0.000 description 2
- 206010048038 Wound infection Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 208000015294 blood coagulation disease Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000008151 electrolyte solution Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 210000003194 forelimb Anatomy 0.000 description 2
- 239000003193 general anesthetic agent Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 238000002350 laparotomy Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 229920000098 polyolefin Polymers 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 238000000528 statistical test Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000006794 tachycardia Effects 0.000 description 2
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical compound CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
- BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
- WSSSPWUEQFSQQG-UHFFFAOYSA-N 4-methyl-1-pentene Chemical compound CC(C)CC=C WSSSPWUEQFSQQG-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241001535291 Analges Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101000804918 Mus musculus Xenotropic and polytropic retrovirus receptor 1 Proteins 0.000 description 1
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000000071 blow moulding Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- PNMUAGGSDZXTHX-UHFFFAOYSA-N glycyl-glutamine Chemical compound NCC(=O)NC(C(O)=O)CCC(N)=O PNMUAGGSDZXTHX-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000011810 insulating material Substances 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005319615A JP5177785B2 (ja) | 2004-11-02 | 2005-11-02 | 周術期患者用薬剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004319375 | 2004-11-02 | ||
| JP2004319375 | 2004-11-02 | ||
| JP2005219281 | 2005-07-28 | ||
| JP2005219281 | 2005-07-28 | ||
| JP2005319615A JP5177785B2 (ja) | 2004-11-02 | 2005-11-02 | 周術期患者用薬剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007055992A JP2007055992A (ja) | 2007-03-08 |
| JP2007055992A5 JP2007055992A5 (enExample) | 2008-12-18 |
| JP5177785B2 true JP5177785B2 (ja) | 2013-04-10 |
Family
ID=37919777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005319615A Expired - Fee Related JP5177785B2 (ja) | 2004-11-02 | 2005-11-02 | 周術期患者用薬剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5177785B2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI445540B (zh) * | 2007-04-20 | 2014-07-21 | Ajinomoto Kk | 抗低體溫組成物 |
| JP2011241149A (ja) * | 2010-05-14 | 2011-12-01 | Terumo Corp | 消化態経口栄養剤 |
| JP5997425B2 (ja) * | 2011-08-18 | 2016-09-28 | 協和発酵バイオ株式会社 | オルニチン含有組成物 |
| JP2014159381A (ja) * | 2013-02-19 | 2014-09-04 | Kyowa Hakko Bio Co Ltd | オルニチン含有体組成改善用組成物 |
| JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
| MA49906A (fr) | 2017-08-14 | 2020-06-24 | Axcella Health Inc | Acides aminés à chaîne ramifiée pour le traitement d'une maladie du foie |
| EP3810123A1 (en) | 2018-06-20 | 2021-04-28 | Axcella Health Inc. | Compositions and methods for the treatment of fat infiltration in muscle |
| CN108721596B (zh) * | 2018-06-29 | 2021-09-21 | 复旦大学附属中山医院 | 一种复方氨基酸维生素注射液及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8704217D0 (sv) * | 1987-10-29 | 1987-10-29 | Vinnars Erik Ab | Aminosyrakomposition for parenteral neringstillforsel |
| JPH02128670A (ja) * | 1988-11-08 | 1990-05-17 | Ajinomoto Co Inc | アミノ酸類含有食品組成物 |
| JPH0710770A (ja) * | 1990-03-14 | 1995-01-13 | Otsuka Pharmaceut Factory Inc | アミノ酸輸液 |
| JPH03264525A (ja) * | 1990-03-14 | 1991-11-25 | Otsuka Pharmaceut Factory Inc | アミノ酸輸液 |
| JPH06227974A (ja) * | 1993-01-29 | 1994-08-16 | Kyowa Hakko Kogyo Co Ltd | 栄養組成物 |
| EP1591116A4 (en) * | 2003-02-06 | 2008-05-28 | Otsuka Pharma Co Ltd | INHIBITOR FOR PERIOPERATIVE BLOOD SUGAR INCREASE |
-
2005
- 2005-11-02 JP JP2005319615A patent/JP5177785B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2007055992A (ja) | 2007-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2889626T3 (es) | Combinación para el tratamiento de la enfermedad de Parkinson | |
| AU2016326749B2 (en) | Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents | |
| KR102093872B1 (ko) | 지방제거용 주사제 조성물 및 이의 제조방법 | |
| JP2005535651A (ja) | グリシンを含有するヒト成長ホルモン（ｈＧＨ）の高濃度液体製剤 | |
| JP2008201778A (ja) | バンコマイシン液状製剤 | |
| CN106659711A (zh) | 呈现长期稳定性的褪黑素注射剂的持久制剂 | |
| ES2906262T3 (es) | Composiciones para el tratamiento de la autodigestión | |
| WO2014061808A1 (ja) | 胃ろう栄養患者用栄養組成物 | |
| JP5177785B2 (ja) | 周術期患者用薬剤 | |
| AU2024312389A1 (en) | Analogues with improved properties | |
| WO2002100193A1 (en) | Body temperature-raising agent of amino acids for eating or drinking and for medical use | |
| KR20100017183A (ko) | 체온 저하 억제제 | |
| JP5298028B2 (ja) | 脳虚血障害治療剤 | |
| CN111701024B (zh) | 一种左旋多巴制剂及其制备方法及其应用 | |
| CA2416600A1 (en) | Freeze-dried preparation of n-¬o-(p-pivaloyloxybenzenesulfonylamino)benzoyl|glycine monosodium salt tetrahydrate and a process for the maufacture thereof | |
| JP5271480B2 (ja) | 体温低下抑制剤 | |
| JP2007137836A (ja) | 末梢静脈栄養輸液 | |
| CN102757471A (zh) | 一种新活性三磷酸胞苷二钠化合物及其药物组合物 | |
| WO2007015585A1 (ja) | 酸化型アルブミン低下剤 | |
| CN102626411A (zh) | 丙泊酚与阿片类镇痛剂的药物组合物及其应用 | |
| JP3975318B2 (ja) | 組織癒着防止剤 | |
| WO2017077425A1 (en) | Oral solution of ace inhibitors | |
| JP2009191015A (ja) | 創傷治癒促進剤 | |
| KR101391551B1 (ko) | 심부전증 예방, 완화 및 치료용 약학 조성물 및 이를 포함하는 복합제제 | |
| JP2681121B2 (ja) | Ｌ−グルタミンのオリゴペプチド配合栄養組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081030 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20081030 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111128 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120127 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120227 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120426 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120625 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120925 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121113 |
|
| A911 | Transfer of reconsideration by examiner before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20121122 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20121217 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20121230 |
|
| LAPS | Cancellation because of no payment of annual fees |